Glucophage Xr (Metformin Hydrochloride)

Glucophage XR is indicated for the oral treatment of type 2 diabetes mellitus, particularly when a stable, long‑acting glucose‑lowering effect is desired.

• Improves glycemic control as part of a comprehensive diabetes management plan.
• Can be used alone (monotherapy) or in combination with other antidiabetic agents such as sulfonylureas, DPP‑4 inhibitors, or insulin.
• Suitable for patients who have difficulty adhering to multiple daily doses of immediate‑release metformin.
• Helps reduce hepatic glucose production and increase peripheral insulin sensitivity.
• May be considered when lifestyle modifications (diet, exercise) are insufficient to achieve target HbA1c levels.

The safety profile of Glucophage XR includes a range of adverse effects that vary in frequency and severity.

Common

• Nausea
• Diarrhea
• Abdominal discomfort
• Flatulence
• Loss of appetite

Serious

• Lactic acidosis (rare but potentially fatal)
• Severe hypoglycemia when combined with insulin or sulfonylureas
• Hepatotoxicity
• Allergic skin reactions such as rash or Stevens‑Johnson syndrome

Before initiating Glucophage XR, clinicians should evaluate several precautionary factors to minimize risks and ensure appropriate use.

• Assess renal function; avoid use in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²).
• Review hepatic status, as liver disease may increase the risk of lactic acidosis.
• Monitor for signs of vitamin B12 deficiency during long‑term therapy.
• Use with caution in elderly patients due to higher susceptibility to renal dysfunction.
• Discontinue before any radiographic studies that use iodinated contrast agents.
• Counsel patients on recognizing symptoms of lactic acidosis, such as unexplained fatigue or rapid breathing.
• Advise against excessive alcohol consumption, which can potentiate lactic acidosis.

Glucophage XR may interact with other medicines, affecting its efficacy or increasing the likelihood of adverse events.

Avoid

• Concomitant use with other biguanides or high‑dose metformin formulations.
• Iodinated contrast media for imaging studies without appropriate renal monitoring.
• Certain cationic drugs (e.g., amiloride, procainamide) that can reduce metformin clearance.

Use with caution

• Sulfonylureas or insulin, which may increase risk of hypoglycemia.
• Loop diuretics (e.g., furosemide) that may impair renal function.
• ACE inhibitors or ARBs, especially in patients with renal insufficiency.
• Alcohol, which can predispose to lactic acidosis.